Advertisement

Science China Life Sciences

, Volume 56, Issue 11, pp 1000–1006 | Cite as

Platelet proteomics and its advanced application for research of blood stasis syndrome and activated blood circulation herbs of Chinese medicine

  • Yue Liu
  • HuiJun YinEmail author
  • KeJi ChenEmail author
Open Access
Review Progress of Projects Supported by NSFC

Abstract

The development of novel and efficient antiplatelet agents that have few adverse effects and methods that improve antiplatelet resistance has long been the focus of international research on the prevention and treatment of cardiovascular and cerebrovascular diseases. Recent advances in platelet proteomics have provided a technology platform for high-quality research of platelet pathophysiology and the development of new antiplatelet drugs. The study of blood stasis syndrome (BSS) and activated blood circulation of traditional Chinese medicine (TCM) is one of the most active fields where the integration of TCM and western medicine in China has been successful. Activated blood circulation herbs (ABC herbs) of Chinese medicine are often used in the treatment of BSS. Most ABC herbs have antiplatelet and anti-atherosclerosis activity, but knowledge about their targets is lacking. Coronary heart disease (CHD), BSS, and platelet activation are closely related. By screening and identifying activated platelet proteins that are differentially expressed in BSS of CHD, platelet proteomics has helped researchers interpret the antiplatelet mechanism of action of ABC herbs and provided many potential biomarkers for BSS that could be used to evaluate the clinical curative effect of new antiplatelet drugs. In this article the progress of platelet proteomics and its advanced application for research of BSS and ABC herbs of Chinese medicine are reviewed.

Keywords

platelet proteomics blood stasis syndrome activated blood circulation coronary heart disease Chinese medicine activated blood circulation herbs 

References

  1. 1.
    Michelson A D. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov, 2010, 9: 154–169PubMedCrossRefGoogle Scholar
  2. 2.
    Gergely F, Andrea F, Gabriella P, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol, 2010, 2: 171–186CrossRefGoogle Scholar
  3. 3.
    Pena A, Collet J P, Hulot J S. Can we override clopidogrel resistance? Circulation, 2009, 119: 2854–2857PubMedCrossRefGoogle Scholar
  4. 4.
    Yang Y L, Liu W J. Research progress of platelet proteomics. J Exp Hematol, 2012, 20: 777–781Google Scholar
  5. 5.
    Di Michele M, Van Geet C, Freson K. Proteomics to unravel platelet-related diseases and identify novel anti-platelet drugs. Curr Med Chem, 2012, 19: 4662–4670PubMedCrossRefGoogle Scholar
  6. 6.
    van der Meijden P E, Heemskerk J W. Platelet protein shake as playmaker. Blood, 2012, 120: 2931–2932PubMedCrossRefGoogle Scholar
  7. 7.
    Di Michele M, Van Geet C, Freson K. Recent advances in platelet proteomics. Expert Rev Proteomics, 2012, 9: 451–466PubMedCrossRefGoogle Scholar
  8. 8.
    Burkhart J M, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood, 2012, 120: e73–82PubMedCrossRefGoogle Scholar
  9. 9.
    Chen K J, Liu Y. Clinical medicine: A holistic integrative medicine in Nature. Med Philos, 2013, 3A: 12–13Google Scholar
  10. 10.
    Chen K J. The Treatment viewpoints and clinical practice of disease identification and syndrome typing (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2011, 31: 1016–1017PubMedGoogle Scholar
  11. 11.
    Zhou H G, Chen H B, Zhou X P, et al. Proteomics is the important technology platform for Chinese medicine pathogenesis research (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2012, 32: 990–993PubMedGoogle Scholar
  12. 12.
    Chen K J, Xue M, Yin H J. The relationship between platelet activation and coronary heart disease and blood stasis syndrome (in Chinese). Shoudu Yi Ke Da Xue Xue Bao, 2008, 29: 266–269Google Scholar
  13. 13.
    Fu C G, Gao Z Y, Wang P L, et al. Study on the diagnostic criteria for coronary heart disease patients of blood stasis syndrome (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2012, 32: 1285–1286PubMedGoogle Scholar
  14. 14.
    Xue M, Chen K J, Yin H J. Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome. Chin J Integr Med, 2008, 14: 267–273PubMedCrossRefGoogle Scholar
  15. 15.
    Li X F. Study on platelet differential functional proteins of blood stasis syndrome in coronary heart disease and drug intervention. Dissertation for Doctoral Degree. Beijing: Xiyuan Hospital, China Academy of Chinese Medical Sciences, 2010Google Scholar
  16. 16.
    Liu Y, Yin H J, Chen K J. Research on the correlation between platelet gelsolin and blood-stasis syndrome of coronary heart disease. Chin J Integr Med, 2011, 17: 587–592PubMedCrossRefGoogle Scholar
  17. 17.
    Liu Y, Yin H J, Jiang Y R, et al. Correlation between platelet gelsolin level and different types of coronary heart disease. Chin Sci Bull, 2012, 57: 631–638CrossRefGoogle Scholar
  18. 18.
    Li G H, Shi Y, Chen Y, et al. Gelsolin regulates cardiac remodeling after myocardial infarction through DNase I-mediated apoptosis. Circ Res, 2009, 104: 896–904PubMedCrossRefGoogle Scholar
  19. 19.
    Liu Y, Jiang Y R, Yin H J, et al. Gelsolin and cardiovascular diseases. Mol Cardiol China, 2011, 11: 50–53Google Scholar
  20. 20.
    Lee W M, Galbraith R M. The extracellular actin scavenger system and actin toxicity. N Engl J Med, 1992, 326: 1335–1341PubMedCrossRefGoogle Scholar
  21. 21.
    Chen K J, Li L D, Weng W L. Blood stasis and research of activating blood circulation and eliminating stasis (in Chinese). Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, 2005, 1: 1–2CrossRefGoogle Scholar
  22. 22.
    Chen K J. Explore the possibilities of Chinese herb and formulas for promoting blood circulation and removing blood stasis on reducing the cardiovascular risk (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008, 5: 389Google Scholar
  23. 23.
    Liu Y, Yin H J, Shi D Z, et al. Chinese herb and formulas of promoting blood circulation and removing blood stasis and antiplatelet therapies. Evid-based Compl Alt Med, 2012, 184503, doi: 10.1155/2012/184503Google Scholar
  24. 24.
    Lu J, Liu J, Shen X P. Application of proteomics in pharmacology of traditional Chinese medicine research. Pharmacol Clin Chin Mater Med, 2012, 28: 243–247Google Scholar
  25. 25.
    Xu H, Wen C, Chen K J, et al. Study on the effect of rhizoma Chuanxiong, radix paeoniae rubra and the compound of their active ingredients, Xiongshao Capsule, on stability of atherosclerotic plaque in ApoE−/− mice (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2007, 27: 513–518PubMedGoogle Scholar
  26. 26.
    Li L Z, Liu J G, Ma L B, et al. Effect of Xiongshao Capsule on lipid metabolism and platelet aggregation in experimental atherosclerosis rabbits (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008, 28: 1100–1103PubMedGoogle Scholar
  27. 27.
    Xu F Q, Xu H, Liu J G, et al. Effects of Xiongshao Capsule on the proliferation of vascular smooth muscle cells in rabbits with atherosclerosis (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008, 28: 912–917PubMedGoogle Scholar
  28. 28.
    Lu X Y, Shi D Z, Xu H, et al. Clinical study on effect of Xiongshao Capsule on restenosis after percutaneous coronary intervention (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2006, 26: 13–17PubMedGoogle Scholar
  29. 29.
    Chen K J, Shi D Z, Xu H, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J (Engl), 2006, 119: 6–13Google Scholar
  30. 30.
    Liu Y. Study on the role of platelet cytoskeletal protein gelsolin in the development of blood stasis syndrome in coronary heart disease and intervention mechanism of effective components of Chuanxiong rhizome and red peony root. Dissertation for Doctoral Degree. Beijing: Xiyuan hospital, China Academy of Chinese Medical Sciences, 2012Google Scholar
  31. 31.
    Liu Y, Yin H J, Jiang Y R, et al. Correlation between platelet gelsolin and platelet activation level in acute myocardial infarction rats and intervention effect of effective components of Chuanxiong rhizome and red peony root. Evid Based Compl Alternat Med, 2013, 985746, doi: 10.1155/2013/985746Google Scholar
  32. 32.
    Yao Y, Wu W Y, Guan S H, et al. Proteomic analysis of differential protein expression in rat platelets treated with notoginsengnosides. Phytomedicine, 2008, 15: 800–807PubMedCrossRefGoogle Scholar
  33. 33.
    Ma C, Yao Y, Yue Q X, et al. Differential proteomic analysis of platelets suggested possible signal cascades network in platelets treated with salvianolic acid B. PLoS ONE, 2011, 6: e14692PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Xu H, Chen K J. Complementary and alternative medicine: Is it possible to be mainstream? Chin J Integr Med, 2012, 18: 403–404PubMedCrossRefGoogle Scholar
  35. 35.
    Wang T. Chinese medicine needs the baptism of science (in Chinese). Zhongguo Zhong Xi Yi Jie He Za Zhi, 2012, 32: 1014–1022PubMedGoogle Scholar
  36. 36.
    Xie M. The logical proposition and significance of “correlation between formula and syndrome” of Chinese medicine. J Beijing Univ Chin Med, 2003, 26: 11–12Google Scholar

Copyright information

© The Author(s) 2013

Authors and Affiliations

  1. 1.Cardiovascular Diseases CentreXiyuan Hospital of China Academy of Chinese Medical SciencesBeijingChina
  2. 2.China Heart Institute of Chinese MedicineChina Academy of Chinese Medical SciencesBeijingChina

Personalised recommendations